Exact Mass: 660.2107702000001
Exact Mass Matches: 660.2107702000001
Found 63 metabolites which its exact mass value is equals to given mass value 660.2107702000001
,
within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error
0.01 dalton.
2)-rhamnoside
2''-O-Rhamnosylicariside II is a flavonoid glycoside compound and might be beneficial for improving postmenopausal osteoporosis.
Calyflorenone A
(1S,3R,4S,5R)-4-[(4-carboxy-3-hydroxy-3-methylbutanoyl)oxy]-3,5-bis({[(2E)-3-(3,4-dihydroxyphenyl)prop-2-enoyl]oxy})-1-hydroxycyclohexane-1-carboxylic acid
3,4-Di-O-caffeoyl-5-O-(3-hydroxy-3-methyl) glutaroyl quinic acid|3,4-dicaffeoyl-5-(3-hydroxy-3-methylglutaroyl)quinic acid
3,4-methylenedioxy-4-methoxy-5-alpha-L-arabinopyranosyloxy-7-beta-D-glucopyranosyloxy-2,7-cycloligna-7,7-dien-9,9-olide|reticulatuside A
4-[6-O-(5-O-(dimethoxycinnamic acid)-beta-apiofuranosyl)-beta-glucopyranoside]-5-methylcoumarin
12-O-desacetyl-12-O-benzoylpteroidine
C34H41ClO11 (660.2337266000001)
3-O--catechin-<5,6-e>-4beta-(3,4-dihydroxyphenyl)-dihydro-2(3H)-pyranone
2-O-RHAMNOSYLICARISIDE II
2''-O-Rhamnosylicariside II is a flavonoid glycoside compound and might be beneficial for improving postmenopausal osteoporosis.
5-hydroxy-7-(4-hydroxyphenyl)-2-methyl-2-[[(2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-[[(2R,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxymethyl]oxan-2-yl]oxymethyl]pyrano[3,2-g]chromen-6-one
(3R,5R)-4-(4-carboxy-3-hydroxy-3-methylbutanoyl)oxy-3,5-bis[[(E)-3-(3,4-dihydroxyphenyl)prop-2-enoyl]oxy]-1-hydroxycyclohexane-1-carboxylic acid
(3R,5R)-4-(4-carboxy-3-hydroxy-3-methylbutanoyl)oxy-3,5-bis[[(E)-3-(3,4-dihydroxyphenyl)prop-2-enoyl]oxy]-1-hydroxycyclohexane-1-carboxylic acid [IIN-based: Match]
(3R,5R)-4-(4-carboxy-3-hydroxy-3-methylbutanoyl)oxy-3,5-bis[[(E)-3-(3,4-dihydroxyphenyl)prop-2-enoyl]oxy]-1-hydroxycyclohexane-1-carboxylic acid [IIN-based on: CCMSLIB00000848162]
(1S,3R,4S,5R)-4-[(4-carboxy-3-hydroxy-3-methylbutanoyl)oxy]-3,5-bis({[(2E)-3-(3,4-dihydroxyphenyl)prop-2-enoyl]oxy})-1-hydroxycyclohexane-1-carboxylic acid_4.5\\%
(1S,3R,4S,5R)-4-[(4-carboxy-3-hydroxy-3-methylbutanoyl)oxy]-3,5-bis({[(2E)-3-(3,4-dihydroxyphenyl)prop-2-enoyl]oxy})-1-hydroxycyclohexane-1-carboxylic acid_minor
(1S,3R,4S,5R)-4-[(4-carboxy-3-hydroxy-3-methylbutanoyl)oxy]-3,5-bis({[(2E)-3-(3,4-dihydroxyphenyl)prop-2-enoyl]oxy})-1-hydroxycyclohexane-1-carboxylic acid_major
2,7-Bis(9H-fluoren-2-yl)-4,9-diphenylpyrido[2,3-g]quinoline
(-)-1,2-BIS((2R,5R)-2,5-DIETHYLPHOSPHOLANO)BENZENE(CYCLOOCTADIENE)RHODIUM(L)TETRAFLUOROBORATE
C30H48BF4P2Rh (660.2315275999999)
butane-1,4-diol,1,3-diisocyanato-2-methylbenzene,hexanedioic acid,1-isocyanato-4-[(4-isocyanatophenyl)methyl]benzene
Hexafluronium Bromide
C36H42Br2N2 (660.1714532000001)
D002317 - Cardiovascular Agents > D000959 - Antihypertensive Agents > D006584 - Hexamethonium Compounds D018377 - Neurotransmitter Agents > D018678 - Cholinergic Agents > D018680 - Cholinergic Antagonists C78272 - Agent Affecting Nervous System > C29698 - Antispasmodic Agent C471 - Enzyme Inhibitor > C47792 - Acetylcholinesterase Inhibitor
(11bR)-2,6-Bis([1,1-biphenyl]-4-yl)-8,9,10,11,12,13,14,15-octahydro-4-hydroxy-4-oxide-dinaphtho[2,1-d:1,2-f][1,3,2]dioxaphosphepin
alpha-D-glucopyranosyl-(1->3)-6-deoxy-alpha-L-mannopyranosyl-(1->2)-6-deoxy-alpha-L-mannopyranosyl-(1->3)-2-O-acetyl-6-deoxy-alpha-L-mannopyranose
4-O-(4-Carboxy-3-hydroxy-3-methylbutanoyl)-3,5-di-O-caffeoylquinic acid
5-hydroxy-7-(4-hydroxyphenyl)-2-methyl-2-[[(2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-[[(2R,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxymethyl]oxan-2-yl]oxymethyl]pyrano[3,2-g]chromen-6-one
Elloramycin A
A member of the class of tetracenomycins that is 8-demethyltetracenomycin C in which the hydroxyl hydrogens at position 8 and 10 a are replaced by a 2,3,4-tri-O-methyl-alpha-L-rhamnosyl and methyl groups respectively.